Editas Medicine Inc   (EDIT)
Other Ticker:  
Price: $8.0600 $0.25 3.201%
Day's High: $8.17 Week Perf: 1.38 %
Day's Low: $ 7.67 30 Day Perf: 3.6 %
Volume (M): 1,499 52 Wk High: $ 11.91
Volume (M$): $ 12,082 52 Wk Avg: $8.55
Open: $7.67 52 Wk Low: $6.08

 Market Capitalization (Millions $) 658
 Shares Outstanding (Millions) 82
 Employees -
 Revenues (TTM) (Millions $) 25
 Net Income (TTM) (Millions $) -195
 Cash Flow (TTM) (Millions $) -128
 Capital Exp. (TTM) (Millions $) 4

Editas Medicine Inc
Editas Medicine Inc is a leading biotechnology company that specializes in developing CRISPR gene editing technology for therapeutic purposes. The company aims to improve patients' lives by treating and potentially curing genetic diseases through precise editing of their DNA. Editas Medicine uses its proprietary genome editing platform to address a wide range of genetic diseases, including rare and inherited conditions. The company focuses on developing innovative therapies and partnering with other organizations to bring these treatments to patients. Editas Medicine is at the forefront of the gene editing field and has the potential to revolutionize medicine by providing targeted and personalized treatments.

   Company Address: 11 Hurley Street Cambridge 2141 MA
   Company Phone Number: 401-9000   Stock Exchange / Ticker: NASDAQ EDIT
   EDIT is expected to report next financial results on February 28, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Licensing Agreement

Revolutionizing Medicine: Editas Medicine and Vertex Pharmaceuticals Forge Path to Innovative Gene Therapies with Cas9 License Agreement

Published Wed, Dec 13 2023 2:00 PM UTC

Editas Medicine, a leading gene editing company, and Vertex Pharmaceuticals, a renowned biotechnology company, have announced their collaboration through a non-exclusive license agreement for Cas9. The license will specifically cover the use of CASGEVY (exagamglogene autotemcel), a groundbreaking gene therapy being developed by Vertex Pharmaceuticals.Gene editing, particular...

Clinical Study

Editas Medicine Presents Exciting Results for EDIT-301 and Achieves Astounding Revenue Growth

Published Mon, Dec 11 2023 5:00 PM UTC

Editas Medicine, a renowned biotechnology company focused on developing transformative genome editing treatments, has recently shared groundbreaking safety and efficacy data for their innovative therapy, EDIT-301. These encouraging results were presented at the American Society of Hematology (ASH) Annual Meeting, as well as in a company-sponsored webinar. Moreover...

Editas Medicine Inc

Editas Medicine Inc. Witnessing a Revolutionary Turnaround: Revenue Skyrockets as Losses Plummet

Editas Medicine Inc, a clinical-stage genome editing company, has reported its fiscal third-quarter results for 2023, showing a decrease in losses compared to the previous year. The company saw a decrease in its loss per share from $-0.81 to $-0.55, and an improvement in its income per share, which went from $-0.56 to an undisclosed positive value.
One of the most significant highlights of the financial report is the sharp increase in revenue. The revenue surged by an impressive 12,604.762% to $5.34 million, compared to the meager $0.04 million reported during the same quarter in the previous year. There was also strong sequential growth, with revenue surging by 84.829% from $2.89 million in the preceding quarter.

Editas Medicine Inc

Editas Medicine Inc Faces Rough Second Quarter with Decline in Financial Performance from April to June 2023

Editas Medicine Inc (NASDAQ: EDIT) has experienced a decline in its shares over the last five trading days, with a decrease of -1.48%. Despite this recent decrease, the year-to-date performance of Editas Medicine Inc is still positive at 2.49%. The company's shares are also trading 36.7% above its 52-week low, indicating a relatively strong performance in the market.
Looking at the second quarter of 2023 earnings season, Editas Medicine Inc managed to decrease its loss per share from $-0.78 to $-0.56 compared to the same period last year. Additionally, the company's income per share improved from $-0.71 to $-0.56, indicating some positive growth.


Editas Medicine Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com